Indications: It is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of sitagliptin and metformin as separate tablets.
Dosage & Administration: The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. This medicine should generally be given twice daily with meals, With gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Or, as directed by total daily dose and the dose of metformin already being taken. Or, asdirected by the registered physician.
Use in Pregnency & Lactation: Sliptin-M has been assigned to pregnancy category B by the FDA.